| Literature DB >> 25028616 |
Anwar Hamade1, Agnieszka Pozdzik2, O Denis3, Monika Tooulou3, Caroline Keyzer4, F Jacobs5, Jose Khabbout6, Joëlle L Nortier2.
Abstract
Mycobacterium fortuitum is a ubiquitous, rapidly growing nontuberculous mycobacterium (NTM). It is the most commonly reported NTM in peritoneal dialysis (PD) associated peritonitis. We report a case of a 52-year-old man on PD, who developed refractory polymicrobial peritonitis necessitating PD catheter removal and shift to hemodialysis. Thereafter, M. fortuitum was identified in the PD catheter culture and in successive cultures of initial peritoneal effluent and patient was treated with amikacin and ciprofloxacin for six months with a good and sustained clinical response. Months after completion of the course of antibiotics, the patient successfully returned to PD. To our knowledge, this is the first reported case of M. fortuitum peritonitis in the field of polymicrobial PD peritonitis. It demonstrates the diagnostic yield of pursuing further investigations in cases of refractory PD peritonitis. In a systematic review of the literature, only 20 reports of M. fortuitum PD peritonitis were identified. Similar to our case, a delay in microbiological diagnosis was frequently noted and the Tenckhoff catheter was commonly removed. However, the type and duration of antibiotic therapy varied widely making the optimal treatment unclear.Entities:
Year: 2014 PMID: 25028616 PMCID: PMC4083769 DOI: 10.1155/2014/323757
Source DB: PubMed Journal: Case Rep Nephrol ISSN: 2090-665X
Figure 1Time course of antibiotherapy and PD effluent parameters.
Figure 2Radiologic findings. (a) Abdominal X-ray showing the PD catheter tip position in the right iliac fossa (white arrow). (b) Computerised tomography of the abdomen, showing the catheter tip resting in close contact with the pelvic wall and the colon (white arrow). (c) Computerised tomography of the abdomen, showing inflamed fat and bowel wall thickening (small white arrow).
M. fortuitum PD-related peritonitis: patient characteristics, antibiotic therapies, and outcome.
| Case | Age | Cause of | Time on PD | Antibiotic therapy | Treatment | PD | Outcome |
|---|---|---|---|---|---|---|---|
| 1 | 32/M | NA | NA | Amikacin, tetracycline | Months | Yes | Resistant |
|
| |||||||
| 2 | 42/M | DN | NA | Amikacin, doxycycline | 20 days | Yes | Recovery |
|
| |||||||
| 3 | 40/M | DN | 24 | Amikacin | 21 days | Yes | Death |
|
| |||||||
| 4 | 16/M | SLE | 36 | Ciprofloxacin | Months | Yes | Recovery |
|
| |||||||
| 5 | 35/M | GN | 10 | Amikacin | NA | Yes | Recovery |
|
| |||||||
| 6 | 71/M | GN | 10 | Amikacin | 3 months | Yes | Recovery |
|
| |||||||
| 7 | 83/F | NS | 11 | Ciprofloxacin | 3 months | No | Recovery |
|
| |||||||
| 8 | 61/M | GN | 0.33 | Amikacin | 1 week | Yes | Recovery |
|
| |||||||
| 9 | 50/M | GN | 96 | Imipenem | NA | Yes | Improved |
|
| |||||||
| 10 | 33/M | HK | NA | Clarithromycin | 6 months | Yes | Improved |
|
| |||||||
| 11 | 71/F | AED | <1 | Amikacin | 3 months | Yes | Death |
|
| |||||||
| 12 | 45/F | NA | 36 | Isoniazid | 6 months | Yes | Recovery |
|
| |||||||
| 13 | 65/M | NA | 60 | Levofloxacin | 12 months | No | Recovery |
|
| |||||||
| 14 | 59/M | NS | 1 | Vancomycin | 1 month | Yes | Recovery |
|
| |||||||
| 15 | 65/M | DN | NA | Minocycline | 6 days | Yes | Recovery |
|
| |||||||
| 16 | 38/F | HUS | 6 | Moxifloxacin, clarithromycin, and doxycycline | NA | Yes | Recovery |
|
| |||||||
| 17 | 62/M | DN | 9 | Cefoxitin, clarithromycin | Weeks | Yes | Recovery |
|
| |||||||
| 18 | 47/M | DN | 6 | Clarithromycin, meropenem, | 2 months | Yes | Recovery |
|
| |||||||
| 19 | 68/F | DN | 48 | Amikacin, ciprofloxacin | 6 months | Yes | Death |
|
| |||||||
| 20 | 15/M | NA | NA | Amikacin, | NA | Yes | NA |
AED: atheroembolic disease; DN: diabetic nephropathy; ESKD: end-stage kidney disease; GN: glomerulonephritis; HK: horseshoe kidney; HUS: hemolytic uremic syndrome; NA: not available; NS: hypertensive nephrosclerosis; PD: peritoneal dialysis; SLE: lupus nephritis.